Nasdaq:BIVI
BIOVIE INC.
A clinical-stage biotechnology company with zero revenue but a positive cash balance funding its extensive R&D pipeline.
Key Metrics
Investment Thesis
Bull Case
An investor might buy BIVI if they believe in the high-risk/high-reward potential of its drug candidates which could generate substantial value upon successful FDA approval and commercialization. The company's strong cash position of $17.5M allows for continued investment in its pipeline without immediate dilution from equity offerings, protecting shareholder value during critical development phases. Success in clinical trials could lead to a multi-bagger return as the company transitions from a loss-making entity to a revenue-generating biotech firm.
Bear Case
Investors should avoid BIVI due to the complete absence of revenue streams and zero gross profit for five years, making it a speculative asset with no current earnings power. The widening net losses from -$50.3M in 2023 to -$17.5M recently suggest ongoing high burn rates that will eventually deplete cash reserves if milestones are missed. With a massive retained earnings deficit of -$352.1M and no commercial products, the company relies entirely on future success rather than current operational performance.
About BIOVIE INC.
BIOVIE INC. (BIVI) is a biotechnology firm focused on developing novel therapies, currently operating with minimal revenue generation as reflected in its zero reported income. The company serves the broader pharmaceutical and healthcare markets through strategic R&D initiatives aimed at addressing unmet medical needs. Key financial indicators show significant investment in research and development totaling $9.3M while maintaining a net cash position of $17.5M.
Analysis
Management Discussion
Management has successfully preserved liquidity by maintaining a healthy cash balance of $17.5M against minimal liabilities, yet the company continues to post substantial net losses driven by $18.1M in operating expenses. Despite generating interest income of $853k which partially offsets operational deficits, the core business model remains pre-revenue with no product sales to date. The retained earnings deficit stands at -$352.1M, indicating historical burn that must be addressed through future milestone achievements.
Industry Overview
The biotechnology industry is characterized by long development cycles, high capital requirements for R&D, and significant regulatory hurdles before products can reach market. Companies in this space often operate at a loss for years while advancing drug candidates through clinical trials before generating any commercial revenue. Success depends on scientific breakthroughs and the ability to secure partnerships or funding to sustain operations until product launch.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $45.1M | $32.2M | $18.1M |
| Operating Income | $-45.1M | $-32.2M | $-18.1M |
| R&D | $33.3M | $23.1M | $9.3M |
| G&A | $11.6M | $8.8M | $8.6M |
| Stock-Based Comp | $4.2M | — | — |
| Amortization | $229.4K | — | — |
| Other OpEx | $229.4K | $229.4K | $229.4K |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $4.3M | $2.9M | — |
| Interest Income | $562.3K | $1.1M | $853.0K |
| Pre-Tax Income | $-45.1M | $-32.2M | $-18.1M |
| Income Tax | $5.2M | $-59.1K | $-524.1K |
| Continuing Ops | $-50.3M | $-32.1M | $-17.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-50.3M | $-32.1M | $-17.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-50.3M | $-32.1M | $-17.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $34.0M | $24.0M | $20.7M |
| Cash & Equivalents | $19.5M | $23.8M | $17.5M |
| Prepaid Expenses | — | — | $1.0M |
| Other Current Assets | $14.6M | $204.4K | $2.1M |
| Long-Term Assets | $1.1M | $1.2M | $863.7K |
| Intangibles | $637.1K | $407.7K | $178.3K |
| Goodwill | $345.7K | $345.7K | $345.7K |
| Operating Leases | $80.8K | $406.7K | $339.7K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $35.1M | $25.2M | $21.6M |
| Current Liabilities | $14.5M | $9.4M | $2.3M |
| Accounts Payable | $3.5M | $3.6M | $2.2M |
| Current Leases | $44.9K | $60.3K | $74.5K |
| Other Current Liab | $11.0M | $5.7M | $0 |
| Long-Term Liabilities | $5.3M | $349.9K | $275.4K |
| LT Operating Leases | $42.5K | $349.9K | $275.4K |
| Other LT Liab | $5.2M | $0 | $0 |
| Total Liabilities | $19.8M | $9.7M | $2.6M |
| Shareholders' Equity | $15.3M | $15.5M | $19.0M |
| Retained Earnings | $-301.2M | $-334.2M | $-352.1M |
| AOCI | $176.6K | — | — |
| Treasury Stock | $2 | $27 | $29 |
| Total L&E | $35.1M | $25.2M | $21.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-50.3M | — | — |
| Non-Cash Adjustments | $10.4M | — | — |
| Working Capital Changes | $-350.3K | — | — |
| Cash from Operations | $-40.3M | — | — |
| Cash from Investing | $-14.3M | — | — |
| Cash from Financing | $55.4M | — | — |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $819.2K | — | — |
| Beginning Cash | $18.6M | — | — |
| Ending Cash | $19.5M | — | — |
Frequently Asked Questions
How does BIOVIE INC. make money?
The company's operations are concentrated entirely in the Research and Development segment, evidenced by $9.3M in R&D expenses and no recorded cost of revenue or gross profit. All financial activity is directed toward advancing pre-clinical or clinical stage assets without current commercial product sales or licensing revenue streams.
What are the main risks for BIVI?
The company faces extreme revenue risk as it has recorded zero revenue for five consecutive years with no commercial products on the market yet. Significant operating expense risks include high burn rates, with net losses widening from -$17.5M in 2024 to a projected trend of increasing deficits if milestones are not met. The lack of diversified income sources means the entire valuation is dependent on successful clinical trials and future licensing deals.
What is BIVI's competitive advantage?
The primary competitive advantage lies in the substantial cash reserve of $17.5M which provides sufficient runway to advance multiple drug candidates without immediate need for capital raising. The company maintains a strong balance sheet with current assets of $20.7M significantly outweighing total liabilities of only $2.6M, offering financial flexibility. Intellectual property generated from the $9.3M annual R&D spend serves as the core asset portfolio.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.